AAPL
64
11
GME
54
-3
EMR
64
-3
KSS
26
2
EA
50
-2
AVGO
88
27
HAS
32
-5
KMX
66
-2
SIG
54
2
PEG
55
2
FAST
46
-3
TAP
60
2
PLD
43
-2
MAR
62
-3
DNB
58
2
MAC
67
2
GLW
42
-3
NKE
37
-3
STZ
54
2
UNH
44
2
AAPL
64
11
GME
54
-3
EMR
64
-3
KSS
26
2
EA
50
-2
AVGO
88
27
HAS
32
-5
KMX
66
-2
SIG
54
2
PEG
55
2
FAST
46
-3
TAP
60
2
PLD
43
-2
MAR
62
-3
DNB
58
2
MAC
67
2
GLW
42
-3
NKE
37
-3
STZ
54
2
UNH
44
2
Financhill
Back

Viridian Therapeutics 10K Form

Sell
10

VRDN
Viridian Therapeutics

Last Price:
17.86
Seasonality Move:
4.07%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive VRDN News And Ratings

See the #1 stock for the next 7 days that we like better than VRDN

VRDN Financial Statistics

Sales & Book Value

Annual Sales: $314K
Cash Flow: $-68M
Price / Cash Flow: 0
Annual Sales: $6.55
Price / Book: 2.75

Profitability

EPS (TTM): -4.31000
Net Income (TTM): $-257.08M
Gross Margin: $790K
Return on Equity: -50.51%
Return on Assets: -45.79%

Viridian Therapeutics Earnings Forecast

Key Viridian Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for VRDN is 23.65%.
  • The Selling, General & Administrative Expenses for VRDN have been equal to 30,254.46% of Gross Profit Margin.
  • The Research & Development expenses have been 50,880.57% of Revenue.
  • The Interest Expense is -0.78% of Operating Income.
  • The Net Earning history of VRDN is -75,711.46% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 7 years.

Viridian Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: VRDN
Website: viridiantherapeutics.com

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 18.55
Quick Ratio: 18.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

VRDN Technical Analysis vs Fundamental Analysis

Sell
10
Viridian Therapeutics (VRDN) is a Sell

Is Viridian Therapeutics a Buy or a Sell?